This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Pathogenesis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

The Gorlin-Goltz syndrome gene has been mapped to chromosome 9q22.3-q31 - there is accumulating evidence suggests that a gene at this locus normally functions as a tumour suppressor. Other genes nearby may also need to be modified or deleted to allow full development of the syndrome - a multiple 'hit' hypothesis. The trigger for mutation may be sunlight and with a fairly rapid lag time, usually months, compared to the development of BCC's in non-Gorlin's individuals. Inheritance of the gene defect seems to be autosomal dominant with variable penetrance.

As a result of a tumour suppressor abnormality, patients with Gorlin-Goltz syndrome are predisposed to develop several neoplasms including cutaneous melanoma, medulloblastoma, meningioma, breast carcinoma, non-Hodgkin's lymphoma and ovarian fibroma (1,2). However, iin contrast to other autosomal dominant cancer predisposition syndromes, developmental malformations, hamartomas, and dysplastic lesions are consistent and striking components of Gorlin-Goltz syndrome (1,2)

 

Ref:

(1) R.J. Gorlin, Nevoid basal cell-carcinoma syndrome [review]. Medicine (Baltimore) 66 (1987), pp. 98-113

(2) R.J. Gorlin, Nevoid basal cell carcinoma syndrome [review]. Dermatol Clin 13 (1995), pp. 113-125.


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.